Literature DB >> 12910249

Virally targeted therapies for EBV-associated malignancies.

Bruce F Israel1, Shannon C Kenney.   

Abstract

In Epstein-Barr virus (EBV)-positive lymphomas, the presence of the EBV genome in virtually all tumor cells, but very few normal cells, suggests that novel, EBV-targeted therapies could be used to treat these malignancies. In this paper, we review a variety of different approaches currently under development that specifically target EBV-infected cells for destruction. EBV-based strategies for treating cancer include prevention of viral oncogene expression, inducing loss of the EBV episome, the purposeful induction of the lytic form of EBV infection, and enhancing the host immune response to virally encoded antigens.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12910249     DOI： 10.1038/sj.onc.1206548

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  39 in total

1.  Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.

Authors:  Sajal K Ghosh; Susan P Perrine; Robert M Williams; Douglas V Faller
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Bendamustine reactivates latent Epstein-Barr virus.

Authors:  Samantha G Fernandez; J J L Miranda
Journal:  Leuk Lymphoma       Date:  2015-09-15

Review 3.  Kleemeier Award Lecture 2008--the canary in the coal mine: telomeres and human healthspan.

Authors:  Rita B Effros
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-02-19       Impact factor: 6.053

Review 4.  Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.

Authors:  Shannon Kenney
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

Review 5.  Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.

Authors:  Abhik Saha; Erle S Robertson
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

6.  Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors.

Authors:  Derek Daigle; Cynthia Megyola; Ayman El-Guindy; Lyn Gradoville; David Tuck; George Miller; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

Review 7.  Regulation of the latent-lytic switch in Epstein-Barr virus.

Authors:  Shannon C Kenney; Janet E Mertz
Journal:  Semin Cancer Biol       Date:  2014-01-20       Impact factor: 15.707

8.  Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.

Authors:  Mei Hong; Yoshihiro Murai; Tomohiko Kutsuna; Hiroyuki Takahashi; Kazuhiro Nomoto; Chun-Mei Cheng; Shin Ishizawa; Qing-Li Zhao; Ryohei Ogawa; Brian V Harmon; Koichi Tsuneyama; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2005-09-23       Impact factor: 4.553

9.  Evaluation of a prediction protocol to identify potential targets of epigenetic reprogramming by the cancer associated Epstein Barr virus.

Authors:  Kirsty Flower; Elizabeth Hellen; Melanie J Newport; Susan Jones; Alison J Sinclair
Journal:  PLoS One       Date:  2010-02-26       Impact factor: 3.240

10.  Epstein-Barr virus latency type and spontaneous reactivation predict lytic induction levels.

Authors:  An T Phan; Samantha G Fernandez; Jessica J Somberg; Kristin M Keck; Jj L Miranda
Journal:  Biochem Biophys Res Commun       Date:  2016-04-16       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.